Cargando…
Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
Alopecia areata (AA) is an immune-mediated condition, clinically manifesting as non-cicatricial patches of alopecia. It is often a self-limiting condition; however, regrowth of hair can take a long period of time, resulting in significant psychological comorbidity. With the recent advances in pathom...
Autores principales: | Sardana, Kabir, Bathula, Savitha, Khurana, Ananta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373824/ https://www.ncbi.nlm.nih.gov/pubmed/37521227 http://dx.doi.org/10.4103/idoj.idoj_452_22 |
Ejemplares similares
-
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
por: Jabbari, Ali, et al.
Publicado: (2015) -
Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
por: Ramírez-Marín, Hassiel Aurelio, et al.
Publicado: (2022) -
An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022) -
Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023) -
A Comment on JAK Inhibitors for Treatment of Alopecia Areata
por: Trüeb, Ralph Michel, et al.
Publicado: (2018)